deSolms SJ - Search Results

1

Design and synthesis of HIV protease inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679.

deSolms SJ, Giuliani EA, Guare JP, Vacca JP, Sanders WM, Graham SL, Wiggins JM, Darke PL, Sigal IS, Zugay JA, et al. deSolms SJ, et al. J Med Chem. 1991 Sep;34(9):2852-7. doi: 10.1021/jm00113a025. J Med Chem. 1991. PMID: 1910089

2

Pseudodipeptide inhibitors of protein farnesyltransferase.

deSolms SJ, Deana AA, Giuliani EA, Graham SL, Kohl NE, Mosser SD, Oliff AI, Pompliano DL, Rands E, Scholz TH, et al. deSolms SJ, et al. J Med Chem. 1995 Sep 29;38(20):3967-71. doi: 10.1021/jm00020a010. J Med Chem. 1995. PMID: 7562930

3

A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.

Holloway MK, Wai JM, Halgren TA, Fitzgerald PM, Vacca JP, Dorsey BD, Levin RB, Thompson WJ, Chen LJ, deSolms SJ. Holloway MK, et al. Among authors: desolms sj. J Med Chem. 1995 Jan 20;38(2):305-17. doi: 10.1021/jm00002a012. J Med Chem. 1995. PMID: 7830273

4

Pseudopeptide inhibitors of Ras farnesyl-protein transferase.

Graham SL, deSolms SJ, Giuliani EA, Kohl NE, Mosser SD, Oliff AI, Pompliano DL, Rands E, Breslin MJ, Deana AA, et al. Graham SL, et al. Among authors: desolms sj. J Med Chem. 1994 Mar 18;37(6):725-32. doi: 10.1021/jm00032a004. J Med Chem. 1994. PMID: 8145221

5

N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.

deSolms SJ, Giuliani EA, Graham SL, Koblan KS, Kohl NE, Mosser SD, Oliff AI, Pompliano DL, Rands E, Scholz TH, Wiscount CM, Gibbs JB, Smith RL. deSolms SJ, et al. J Med Chem. 1998 Jul 2;41(14):2651-6. doi: 10.1021/jm9800907. J Med Chem. 1998. PMID: 9651171

6

Potent, non-thiol inhibitors of farnesyltransferase.

Breslin MJ, deSolms SJ, Giuliani EA, Stokker GE, Graham SL, Pompliano DL, Mosser SD, Hamilton KA, Hutchinson JH. Breslin MJ, et al. Among authors: desolms sj. Bioorg Med Chem Lett. 1998 Dec 1;8(23):3311-6. doi: 10.1016/s0960-894x(98)00586-1. Bioorg Med Chem Lett. 1998. PMID: 9873725

7

A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.

Tucker TJ, Lumma WC Jr, Payne LS, Wai JM, de Solms SJ, Giuliani EA, Darke PL, Heimbach JC, Zugay JA, Schleif WA, et al. Tucker TJ, et al. J Med Chem. 1992 Jul 10;35(14):2525-33. doi: 10.1021/jm00092a002. J Med Chem. 1992. PMID: 1635054

8

L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.

Vacca JP, Guare JP, deSolms SJ, Sanders WM, Giuliani EA, Young SD, Darke PL, Zugay J, Sigal IS, Schleif WA, et al. Vacca JP, et al. Among authors: desolms sj. J Med Chem. 1991 Mar;34(3):1225-8. doi: 10.1021/jm00107a050. J Med Chem. 1991. PMID: 2002465 No abstract available.

9

Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide.

Woltersdorf OW Jr, Schwam H, Bicking JB, Brown SL, deSolms SJ, Fishman DR, Graham SL, Gautheron PD, Hoffman JM, Larson RD, et al. Woltersdorf OW Jr, et al. Among authors: desolms sj. J Med Chem. 1989 Nov;32(11):2486-92. doi: 10.1021/jm00131a011. J Med Chem. 1989. PMID: 2810337

10

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.

Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE. Prendergast GC, et al. Among authors: desolms sj. Mol Cell Biol. 1994 Jun;14(6):4193-202. doi: 10.1128/mcb.14.6.4193-4202.1994. Mol Cell Biol. 1994. PMID: 8196657 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters